2026 Q2 Portfolio Activity
In 2026 Q2, CAXTON CORP maintained a portfolio of 11 distinct positions. The most significant new addition was SPACE EXPLORATION TECHN CORP, now representing 24.03% of the total fund value. They heavily accumulated shares in LEXEO THERAPEUTICS INC, increasing the position by 21.7%. Conversely, CAXTON CORP completely exited their position in SPDR GOLD TR.
Position History
hover any row below to update
Loading…
Total Positions
11
Quarter
2026 Q2
Top Holding
N/A (24.0%)
Top 10 Concentration
100.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-11 of 11
CAXTON CORP Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
N/A
SPACE EXPLORATI...
|
|
Unknown | 24.03% | — |
#1
Prev: #—
|
9.5 |
—
|
2,606 | — |
NEW
|
2,606 | $445,346 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
BRK/B
BERKSHIRE HATHA...
|
Financial Services | 20.35% | 8.66% |
#2
Prev: #2
|
6.0 |
—
|
27 | 3.7% |
P
S
|
754 | $377,128 | 2012 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GOOGL
ALPHABET INC
|
Communication Services | 13.32% | — |
#3
Prev: #—
|
8.5 |
—
|
691 | — |
NEW
|
691 | $246,906 | 2019 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
VOO
VANGUARD INDEX ...
|
ETF | 12.58% | — |
#4
Prev: #—
|
8.0 |
—
|
339 | — |
NEW
|
339 | $233,094 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BX
BLACKSTONE INC
|
Financial Services | 10.16% | — |
#5
Prev: #—
|
8.0 |
—
|
1,597 | — |
NEW
|
1,597 | $188,218 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KYTX
KYVERNA THERAPE...
|
Healthcare | 5.94% | 4.03% |
#6
3
Prev: #3
|
2.4 |
—
|
-6,426 | -34.2% |
P
S
|
12,347 | $110,009 | 2012 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LXEO
LEXEO THERAPEUT...
|
Healthcare | 4.26% | 1.99% |
#7
3
Prev: #4
|
4.2 |
—
|
3,019 | 21.7% |
P
S
|
16,962 | $78,959 | 2012 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
XFOR
X4 PHARMACEUTIC...
|
Healthcare | 3.92% | 1.60% |
#8
3
Prev: #5
|
2.6 |
—
|
no change | no change |
P
S
|
15,557 | $72,650 | 2012 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IKT
INHIBIKASE THER...
|
Healthcare | 3.12% | 1.19% |
#9
3
Prev: #6
|
2.2 |
—
|
no change | no change |
P
S
|
28,453 | $57,759 | 2012 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ALXO
ALX ONCOLOGY HL...
|
Healthcare | 2.34% | 1.04% |
#10
3
Prev: #7
|
1.9 |
—
|
no change | no change |
P
S
|
20,946 | $43,358 | 2026 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLD
SPDR GOLD TR
|
ETF | 0.00% | 81.50% |
Sold All 😨
(Was: #1) |
0.0 |
—
|
-7,623 | -100.0% |
CLOSED
|
— | $— | 2012 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-11 of 11 holdings